Home › Funds › Cormorant Asset Management, LP › MLTX

Cormorant Asset Management, LP position in MLTX

MOONLAKE IMMUNOTHERAPEUTICS · Health Care

Cormorant Asset Management, LP reported holding 3,205,433 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$62.4M, representing 3.20% of its reported portfolio and ranking #12 among its reported holdings. Cormorant Asset Management, LP has disclosed MLTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.21M sh
Reported value held$62.41M
Portfolio Weight3.20%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's MLTX position evolved

Cormorant Asset Management, LP first disclosed a stake in MLTX in Q3 2023 at 8,142,100 shares (US$464.1M). The position peaked in Q4 2023 at 8,494,151 shares, worth US$513.0M. Across 12 filings, Cormorant Asset Management, LP increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 3,205,433 shares valued at US$62.4M — a reduction of -1,275,000 shares quarter over quarter.. Notable position changes include a 77% trim in Q3 2025 (shares rose 84% over the following quarter), a 118% increase in Q4 2025 (shares rose 41% over the following quarter), a 28% trim in Q2 2026 (shares fell 40% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.14M $464.10M New
Q4 2023 8.49M $512.96M Add
Q1 2024 8.49M $426.66M Hold
Q2 2024 8.49M $373.49M Hold
Q3 2024 8.49M $428.28M Hold
Q4 2024 8.49M $459.96M Hold
Q1 2025 8.49M $331.87M Hold
Q2 2025 8.49M $400.92M Hold
Q3 2025 1.99M $14.30M Reduce
Q4 2025 4.36M $57.40M Add
Q1 2026 4.48M $83.52M Add
Q2 2026 3.21M $62.41M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MLTX and 13F data

MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 29 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Logos Global Management LP (US$52.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MLTX

All MLTX fund holders →

FAQ

How long has Cormorant Asset Management, LP held MLTX?

Cormorant Asset Management, LP has disclosed MLTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Cormorant Asset Management, LP's current position in MLTX?

As of Q2 2026, Cormorant Asset Management, LP holds 3.21M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $62.41M, representing 3.20% of its reported portfolio and ranking #12.

Has Cormorant Asset Management, LP been buying or selling MLTX?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in MLTX. The position peaked in Q4 2023 at 8.49M shares.

Which other funds hold MLTX?

Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Logos Global Management LP, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.